Reviewing Celcuity (CELC) and The Competition
Celcuity (NASDAQ: CELC) is one of 23 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its rivals? We will compare Celcuity to related companies based on the strength of its earnings, analyst recommendations, profitability, dividends, risk, institutional ownership and valuation.
Risk and Volatility
Celcuity has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Celcuity’s rivals have a beta of 1.33, indicating that their average share price is 33% more volatile than the S&P 500.
15.2% of Celcuity shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Medical laboratories” companies are owned by institutional investors. 43.5% of Celcuity shares are owned by insiders. Comparatively, 16.6% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Celcuity and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Celcuity currently has a consensus price target of $35.50, suggesting a potential upside of 48.23%. As a group, “Medical laboratories” companies have a potential upside of 14.81%. Given Celcuity’s stronger consensus rating and higher probable upside, equities analysts plainly believe Celcuity is more favorable than its rivals.
This table compares Celcuity and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Celcuity and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Celcuity Competitors||$1.13 billion||$90.54 million||442.99|
Celcuity’s rivals have higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Celcuity beats its rivals on 7 of the 13 factors compared.
Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. The company is developing CELx tests to diagnose two new sub-types of HER2-negative breast cancer. It is also developing CELx tests to diagnose 14 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.